Crosstalk Between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2019 Jan 22

PMID 30662458

Citations 21

Authors

Paola Parente

Pietro Parcesepe

Claudia Covelli

Nunzio Olivieri

Andrea Remo

Massimo Pancione

Tiziana Pia Latiano

Paolo Graziano

Evaristo Maiello

Guido Giordano

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma is a lethal disease for which radical surgery and chemotherapy represent the only curative options for a small proportion of patients. Recently, FOLFIRINOX and nab-paclitaxel plus gemcitabine have improved the survival of metastatic patients but prognosis remains poor. A pancreatic tumor microenvironment is a dynamic milieu of cellular and acellular elements, and it represents one of the major limitations to chemotherapy efficacy. The continued crosstalk between cancer cells and the surrounding microenvironment causes immunosuppression within pancreatic immune infiltrate increasing tumor aggressiveness. Several potential targets have been identified among tumor microenvironment components, and different therapeutic approaches are under investigation. In this article, we provide a qualitative literature review about the crosstalk between the tumor microenvironment components and immune system in pancreatic cancer. Finally, we discuss potential therapeutic strategies targeting the tumor microenvironment and we show the ongoing trials.

Citing Articles

Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report.

Fabien M, Elodie P, Anna S, Addeo P, Meher B World J Clin Cases. 2023; 11(6):1372-1378.

PMID: 36926125 PMC: 10013109. DOI: 10.12998/wjcc.v11.i6.1372.

COL12A1 Acts as a Novel Prognosis Biomarker and Activates Cancer-Associated Fibroblasts in Pancreatic Cancer through Bioinformatics and Experimental Validation.

Song Y, Wang L, Wang K, Lu Y, Zhou P Cancers (Basel). 2023; 15(5).

PMID: 36900272 PMC: 10000532. DOI: 10.3390/cancers15051480.

Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma.

Liu Z, Hayashi H, Matsumura K, Uemura N, Shiraishi Y, Sato H Cancers (Basel). 2023; 15(2).

PMID: 36672448 PMC: 9856866. DOI: 10.3390/cancers15020498.

Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers.

Fiore P, Di Pace A, Conti L, Tumino N, Besi F, Scaglione S Cancer Immunol Immunother. 2022; 72(6):1417-1428.

PMID: 36451048 PMC: 10198856. DOI: 10.1007/s00262-022-03340-z.

KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer.

Yang J, Jin L, Kim H, Tian F, Yi Z, Bedi K Cancer Res. 2022; 82(22):4247-4260.

PMID: 36306422 PMC: 9669233. DOI: 10.1158/0008-5472.CAN-22-0968.

References

Yen T, Aardal N, Bronner M, Thorning D, Savard C, Lee S . Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery. 2002; 131(2):129-34. DOI: 10.1067/msy.2002.119192. View

Bourguignon L, Singleton P, Zhu H, Diedrich F . Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor.... J Biol Chem. 2003; 278(32):29420-34. DOI: 10.1074/jbc.M301885200. View

Sawyer J, Anderson B, Beight D, Campbell R, Jones M, Herron D . Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem. 2003; 46(19):3953-6. DOI: 10.1021/jm0205705. View

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. DOI: 10.1038/nrc1877. View

Vonlaufen A, Joshi S, Qu C, Phillips P, Xu Z, Parker N . Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008; 68(7):2085-93. DOI: 10.1158/0008-5472.CAN-07-2477. View

Naber H, Ten Dijke P, Pardali E . Role of TGF-beta in the tumor stroma. Curr Cancer Drug Targets. 2008; 8(6):466-72. DOI: 10.2174/156800908785699342. View

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View

Froeling F, Mirza T, Feakins R, Seedhar A, Elia G, Hart I . Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol. 2009; 175(2):636-48. PMC: 2716963. DOI: 10.2353/ajpath.2009.090131. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

11.

Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F . Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2009; 167(2):e211-9. DOI: 10.1016/j.jss.2009.05.026. View

12.

Kii I, Nishiyama T, Li M, Matsumoto K, Saito M, Amizuka N . Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem. 2009; 285(3):2028-39. PMC: 2804360. DOI: 10.1074/jbc.M109.051961. View

13.

Hidalgo M . Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-17. DOI: 10.1056/NEJMra0901557. View

14.

Rasanen K, Vaheri A . Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010; 316(17):2713-22. DOI: 10.1016/j.yexcr.2010.04.032. View

15.

Kikuta K, Masamune A, Watanabe T, Ariga H, Itoh H, Hamada S . Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun. 2010; 403(3-4):380-4. DOI: 10.1016/j.bbrc.2010.11.040. View

16.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

17.

Bausch D, Pausch T, Krauss T, Hopt U, Fernandez-Del-Castillo C, Warshaw A . Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis. 2011; 14(3):235-43. PMC: 3688040. DOI: 10.1007/s10456-011-9207-3. View

18.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

19.

Reid M, Basturk O, Thirabanjasak D, Hruban R, Klimstra D, Bagci P . Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol. 2011; 24(12):1612-9. PMC: 3227778. DOI: 10.1038/modpathol.2011.113. View

20.

Scarlett C, Colvin E, Pinese M, Chang D, Morey A, Musgrove E . Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One. 2011; 6(10):e26088. PMC: 3193536. DOI: 10.1371/journal.pone.0026088. View